SCHEMBL709174

SCHEMBL709174

CNC(C)C(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801212 1.00
SCHEMBL238192 1.00
Hydrochloric Acid SCHEMBL3943090 0.97
Hydrochloric Acid SCHEMBL238191 0.97
Bromide SCHEMBL10783307 0.97
Hydrochloric Acid SCHEMBL2785010 0.97
Trifluoroacetic Acid SCHEMBL8326752 0.84 CA14 (0.42)
Trifluoroacetic Acid SCHEMBL8326750 0.84 CA14 (0.42)
SCHEMBL12890766 0.83 CA14 (0.45)
SCHEMBL9947502 0.83 CA14 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116273432-A Beneficiation method for comprehensively recovering rubidium from hard rock type lithium multi-metal ore 广东省科学院资源利用与稀土开发研究所 2023-06-23 CN claimed
US-20260008784-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES VASTHERA CO LTD (KR) 2026-01-08 US disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 US disclosed
EP-4547673-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES VASTHERA Co. Ltd. (KR) 2025-05-07 EP disclosed
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-24 US disclosed
CN-119403810-A Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases 瓦斯塞拉股份有限公司 2025-02-07 CN disclosed
CN-119350433-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2025-01-24 CN disclosed
US-12195427-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-01-14 US disclosed
CN-112867706-B MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-11-15 CN disclosed
US-20070213329-A1 Sulphones which modulate the action of gammasecretase MERCK SHARP & DOHME (UK) LIMITED (GB) 2007-09-13 US disclosed
WO-2007014409-A1 PLEUROMUTILIN DERIVATIVES USEFUL AS ANTIBACTERIALS NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) 2007-02-08 WO disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed
EP-0667854-B1 PEPTIDYL ACTIVATED KETONE INHIBITORS CONTAINING NATURAL AND UNNATURAL PEPTIDE SEQUENCES PROTOTEK INC (US) 1999-06-02 EP disclosed
EP-0667854-A1 PEPTIDYL ACTIVATED KETONE INHIBITORS CONTAINING NATURAL AND UNNATURAL PEPTIDE SEQUENCES PROTOTEK, INC., (US) 1995-08-23 EP disclosed
EP-0667854-A4 PEPTIDYL ACTIVATED KETONE INHIBITORS CONTAINING NATURAL AND UNNATURAL PEPTIDE SEQUENCES. PROTOTEK INC (US) 1995-07-04 EP disclosed
US-5374623-A Cysteine protease inhibitors effective for in vivo use PROTOTEK, INC. (US) 1994-12-20 US disclosed
WO-1994004172-A1 PEPTIDYL ACTIVATED KETONE INHIBITORS CONTAINING NATURAL AND UNNATURAL PEPTIDE SEQUENCES PROTOTEK, INC. (US) 1994-03-03 WO disclosed
US-4723031-A Processes for synthesizing substituted and unsubstituted aminoacetate esters CHEVRON RESEARCH COMPANY (US) 1988-02-02 US disclosed